Evidence map›Paper›PMID 39534878›Full record

ArticleOpen research Europe2024

Environmental impacts of drugs against parasitic vector-borne diseases and the need to integrate sustainability into their development and use.

Clara M Lima, Elisa Uliassi, Eli S J Thoré, Michael G Bertram, Luis Cardoso, Anabela Cordeiro da Silva, Maria Paola Costi, Harry P de Koning

Abstract read
In one paragraph

Article in Open research Europe, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Clara M LimaHost-Parasite Interaction Group, Institute for Research and Innovation in Health, University of Porto, 4200-135, Porto, Portugal.
Elisa UliassiDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna, 40126, Italy.ORCID https://orcid.org/0000-0002-0990-2532
Eli S J ThoréDepartment of Wildlife, Fish, and Environmental Studies, Swedish University of Agricultural Sciences, Umea, SE-907 36, Sweden.
Michael G BertramDepartment of Wildlife, Fish, and Environmental Studies, Swedish University of Agricultural Sciences, Umea, SE-907 36, Sweden.ORCID https://orcid.org/0000-0001-5320-8444
Luis CardosoDepartment of Veterinary Sciences, and Animal and Veterinary Research Centre, University of Trás-os-Montes e Alto Douro, Vila Real, 5000-801 Vila Real, Portugal.ORCID https://orcid.org/0000-0002-6145-7560
Anabela Cordeiro da SilvaHost-Parasite Interaction Group, Institute for Research and Innovation in Health, University of Porto, 4200-135, Porto, Portugal.
Maria Paola CostiDepartment of Life Science, University of Modena and Reggio Emilia, Modena, 41125, Italy.ORCID https://orcid.org/0000-0002-0443-5402
Harry P de KoningSchool of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, G12 8TA, UK.ORCID https://orcid.org/0000-0002-0029-8404

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The current scientific discourse on environmental impacts of veterinary medicines mostly focuses on ectoparasiticides. Meanwhile, the environmental impacts of widely prescribed drugs for the treatment of human and animal parasitic vector-borne diseases (PVBD) remain largely unexplored. There is thus a need for evidence-based information to support guidelines and protocols for sustainable One Health PVBD drug development and use, while promoting greener research practices. Here, we reflect on the potential environmental impacts of PVBD drugs in current use, and the environmental impact of our research practices for developing new antiparasitics. Methods: We conducted a survey of the membership of the "One Health drugs against parasitic vector borne diseases in Europe and beyond" Cooperation in Science and Technology (COST) Action 21111 (OneHealth Results: The survey was conducted and analysed by OneHealth Conclusions: We highlight the need for early-ecotoxicological testing of new drug candidates and suggest best practices as we move towards standardized protocols in developing safe and efficacious PVBD drugs.

Indexed as

Drug discoveryEcotoxicologyEnvironmental impactOne HealthParasitic vector-borne diseases

Identifiers

PMID39534878
PMCPMC11555358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.